ERBB2 and breast carcinoma: The effectiveness of RCB (Residual Cancer Burden) as a prognostic marker in patients with residual tumors is 32% and ranges from 22% for HR+/HER2− breast cancers to 44% for HR−/HER2+ breast cancers [4].